137 related articles for article (PubMed ID: 1402660)
1. Engineered humanized dimeric forms of IgG are more effective antibodies.
Caron PC; Laird W; Co MS; Avdalovic NM; Queen C; Scheinberg DA
J Exp Med; 1992 Oct; 176(4):1191-5. PubMed ID: 1402660
[TBL] [Abstract][Full Text] [Related]
2. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
[TBL] [Abstract][Full Text] [Related]
3. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
[TBL] [Abstract][Full Text] [Related]
4. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
5. An antibody with Fab-constant domains exchanged for a pair of CH3 domains.
Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Gotsmy M; Becker S; Rüker F
PLoS One; 2018; 13(4):e0195442. PubMed ID: 29630643
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
8. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.
Liu AY; Robinson RR; Murray ED; Ledbetter JA; Hellström I; Hellström KE
J Immunol; 1987 Nov; 139(10):3521-6. PubMed ID: 3119711
[TBL] [Abstract][Full Text] [Related]
9. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
10. Chimeric and humanized antibodies with specificity for the CD33 antigen.
Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C
J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932
[TBL] [Abstract][Full Text] [Related]
11. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.
Kan KS; Anderson VA; Leong WS; Smith AM; Worth AT; Stevenson GT
J Immunol; 2001 Jan; 166(2):1320-6. PubMed ID: 11145716
[TBL] [Abstract][Full Text] [Related]
12. Fc-dependent monoclonal IgG1-mediated suppression of antibody response.
Kayhan B; Aybay C
Immunol Invest; 2004; 33(4):367-83. PubMed ID: 15624696
[TBL] [Abstract][Full Text] [Related]
13. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
14. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis.
Gadgil HS; Bondarenko PV; Pipes GD; Dillon TM; Banks D; Abel J; Kleemann GR; Treuheit MJ
Anal Biochem; 2006 Aug; 355(2):165-74. PubMed ID: 16828048
[TBL] [Abstract][Full Text] [Related]
15. Mapping the functional topography of Fc gamma with monoclonal antibodies: localization of epitopes interacting with the binding sites of Fc receptor on human K cells.
Sármay G; Jefferis R; Klein E; Benczur M; Gergely J
Eur J Immunol; 1985 Oct; 15(10):1037-42. PubMed ID: 2414110
[TBL] [Abstract][Full Text] [Related]
16. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
17. Activation of complement pathways by univalent antibody derivatives with intact Fc zones.
Watts HF; Anderson VA; Cole VM; Stevenson GT
Mol Immunol; 1985 Jul; 22(7):803-10. PubMed ID: 3849671
[TBL] [Abstract][Full Text] [Related]
18. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
Vaccaro C; Zhou J; Ober RJ; Ward ES
Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
[TBL] [Abstract][Full Text] [Related]
19. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
Gillies SD; Wesolowski JS
Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
[TBL] [Abstract][Full Text] [Related]
20. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
Schirrmann T; Pecher G
Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
